-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

Benzinga·10/08/2026 14:49:09
Listen to the news
RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $299 to $296.